Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics June 4, 2024 Study illuminates CDCA7’s role in DNA methylation August 27, 2024 Sleep deprivation in early life increases autism risk October 24, 2024
Novel small molecule oral antiviral could be a game-changer in the fight against future pandemics June 4, 2024